查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1959968

qPCR設備市場－全球產業規模、佔有率、趨勢、機會、預測：按檢測類型、地區和競爭格局分類，2021-2031年

qPCR Instruments Market- Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 185 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球 qPCR 設備市場預計將從 2025 年的 12.9 億美元成長到 2031 年的 19.4 億美元，複合年成長率為 7.04%。

該市場包含整合熱循環和螢光檢測技術的先進分析平台，透過即時擴增和定量核酸，在生命科學研究和臨床診斷中發揮至關重要的作用。推動這一市場成長的關鍵因素是全球遺傳性疾病和感染疾病需要高靈敏度和快速的分子檢測能力。此外，對基因組研究的持續投入以及個人化醫療通訊協定的廣泛應用，也為這些精準診斷工具的持續需求提供了重要的支撐，確保其在瞬息萬變的技術浪潮中依然具有重要意義。

市場概覽
預測期 2027-2031
市場規模：2025年 12.9億美元
市場規模：2031年 19.4億美元
複合年成長率：2026-2031年 7.04%
成長最快的細分市場 GeneXpert
最大的市場 北美洲

然而，體外診斷領域日益嚴格的法規環境為市場帶來了重大障礙。這給設備製造商帶來了沉重的合規責任。這些複雜的要求往往會導致營運成本增加和產品上市延遲，尤其是在特殊應用領域。據歐洲醫療技術協會（MedTech Europe）稱，到2024年，由於這些資源密集型標準，26.6%的體外診斷設備製造商計劃將其孤兒藥產品組合中不到5%的產品轉移到新的法規結構下。因此，這些監管障礙構成了一項重大挑戰，可能會限制創新檢測解決方案的普及，並阻礙更廣泛的市場成長。

市場促進因素

全球感染疾病和遺傳性疾病負擔日益加重，是推動qPCR設備普及應用的主要動力，也因此對精準快速的分子診斷平台的需求日益成長。隨著病原體的不斷演變和慢性遺傳性疾病盛行率的上升，臨床檢查室高度依賴即時PCR進行高靈敏度的檢測和定量，這對於患者照護至關重要。世界衛生組織（世衛組織）於2025年11月更新的《結核病關鍵事實》預測，2024年全球將有約1,070萬人感染結核病，凸顯了建立健全診斷基礎設施的迫切性。如此沉重的疾病負擔要求我們持續採購qPCR系統，以確保及時檢測和有效控制疫情，這也鞏固了該技術在現代醫學中的重要性。

同時，生命科學研究領域公共和私人資金的大幅成長正在推動下一代基因組學技術的進步。產業領導企業正大力投資研發，以提升設備的自動化程度、處理能力和冗餘性，從而直接滿足市場對更高效率的需求。根據賽默飛世爾科技公司於2025年10月發布的2025年第三季財報，截至2025年9月30日的會計年度，其研發總支出達到14.1億美元，展現了公司對創新持續的財務投入。這項投資支撐了市場的活力，主要企業在經濟波動的情況下依然保持強勁的盈利表現便印證了這一點。例如，凱傑公司在2025年11月發布的2025年第三季財報中指出，截至2025年9月30日的12個月內，其營收達到20.7億美元，支撐了市場對分子檢測解決方案的持續需求。

市場挑戰

全球qPCR儀器市場的發展很大程度上受到體外診斷領域嚴格監管的限制。這種複雜的合規環境給製造商帶來了沉重的營運負擔，需要提供大量的技術文件和嚴謹的臨床證據才能獲得儀器認證。企業被迫重新分配資金和人員以滿足這些高標準，這不可避免地減少了用於研發下一代qPCR平台的資源。因此，先進診斷工具的上市被推遲，製造商也越來越不願意進入合規成本高或核准流程不確定的市場。

這些監管障礙的具體影響體現在主要產業參與者在市場准入方面的策略選擇。根據歐洲醫療技術協會（MedTech Europe）預測，到2024年，選擇歐盟作為其首批產品上市主要區域的領先體外診斷試劑製造商比例將比先前的管理體制下下降40%。這一趨勢表明，合規方面的困難正在積極阻礙新技術的商業化。這些法規透過減緩產品創新步伐和設置市場准入壁壘，直接限制了新解決方案的可用性，並正在扼殺整個qPCR儀器產業的成長。

市場趨勢

製造商正積極研發緊湊型、電池供電的攜帶式qPCR設備，以方便在急診、診所和現場等環境中分散式檢查。這種小型化趨勢使醫療專業人員能夠在臨床環境中進行先進的分子診斷，與傳統的中心檢查室相比，顯著縮短了獲得檢測結果的時間。這些更有效率系統的快速普及體現在市場對專為非檢查室環境設計的平台的需求不斷成長。根據生物梅里埃公司於2025年9月發布的《2025年上半年財務業績報告》，SPOTFIRE照護現場系統的有機銷售額同比成長143%，凸顯了該行業向便捷的、床邊檢測方案的強勁轉變。

同時，在單次反應中識別多個標靶（例如複雜的病原體組合）的需求，正顯著推動高通量檢測能力的提升。檢查室優先選擇能夠同時分析多個通道的儀器，以節省寶貴的患者檢體並提高診斷效率，從而超越基本的單一標靶檢測。這種對全面症候群檢測的需求，正透過整合更廣泛的檢測項目和更高的通道數量，改變產品系列。根據QIAGEN於2025年11月發布的2025年第三季財報，QIAstat-Dx症候群檢測平台的銷售額在不計外匯影響的情況下成長了11%，這表明市場對能夠最佳化工作流程效率的先進多重技術有著強勁的需求。

目錄

第1章概述

第2章：調查方法

第3章執行摘要

第4章：客戶心聲

第5章：全球qPCR儀器市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依測試類型（7500、QuantStudio Dx、QuantStudio 5、ViiA 7 Dx、One Step/One Step Plus、LightCycler 2.0、Cobas 4800、CFX96、SmartCycler、GeneXpert、Rotor-Gene Q 5Plex HRM System System、Rotor-Gene、BI System、RoIL MAY
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美qPCR儀器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國別分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲qPCR儀器市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國別分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區qPCR設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國別分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲qPCR設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東與非洲：國別分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲qPCR設備市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國別分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進因素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 近期趨勢

第13章：全球qPCR儀器市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的議價能力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • QIAGEN NV
  • Agilent Technologies, Inc.
  • Abbott Laboratories Inc.
  • Azure Biosystems Inc.
  • Bio Molecular Systems Pty Ltd

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 24018

The Global qPCR Instruments Market is projected to expand from USD 1.29 Billion in 2025 to USD 1.94 Billion by 2031, registering a CAGR of 7.04%. This market consists of sophisticated analytical platforms that integrate thermal cycling with fluorescence detection to amplify and quantify nucleic acids in real-time, serving essential roles in life sciences research and clinical diagnostics. Key factors fueling this growth include the rising global incidence of genetic disorders and infectious diseases, which require high-sensitivity, rapid molecular testing capabilities. Additionally, sustained investment in genomic research and the broader adoption of personalized medicine protocols act as vital pillars supporting the ongoing demand for these precise diagnostic tools, ensuring their relevance beyond temporary technological shifts.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 1.29 Billion
Market Size 2031USD 1.94 Billion
CAGR 2026-20317.04%
Fastest Growing SegmentGeneXpert
Largest MarketNorth America

However, the market encounters substantial obstacles due to an increasingly strict regulatory environment for in vitro diagnostics, which imposes heavy compliance responsibilities on device manufacturers. These complex requirements often increase operational costs and postpone product launches, particularly affecting specialized applications. According to MedTech Europe, in 2024, 26.6% of in vitro diagnostic manufacturers intended to transition less than 5% of their orphan device portfolios to the new regulatory framework because of these resource-demanding standards. Consequently, such regulatory barriers pose a significant challenge that threatens to limit the accessibility of innovative testing solutions and impede broader market growth.

Market Driver

The increasing global burden of infectious diseases and genetic disorders acts as a major catalyst for the adoption of qPCR instruments, driving the need for precise and rapid molecular diagnostic platforms. As pathogens evolve and the prevalence of chronic genetic conditions grows, clinical laboratories depend heavily on real-time PCR for sensitive detection and quantification essential to patient care. According to the World Health Organization's 'Tuberculosis Key Facts' update in November 2025, an estimated 10.7 million people contracted tuberculosis globally in 2024, highlighting the urgent requirement for strong diagnostic infrastructure. This significant disease burden ensures the continued procurement of qPCR systems to guarantee timely detection and effective outbreak control, cementing the technology's importance in modern healthcare.

Simultaneously, substantial increases in public and private funding for life sciences research are stimulating the advancement of next-generation genomic technologies. Industry leaders are investing heavily in research and development to improve instrument automation, throughput, and multiplexing capabilities, directly responding to market needs for greater efficiency. According to Thermo Fisher Scientific's 'Third Quarter 2025 Earnings Release' in October 2025, R&D expenses for the year ending September 30, 2025, totaled $1.41 billion, demonstrating a sustained financial dedication to innovation. This investment supports market vitality, as shown by major players maintaining robust revenues despite economic volatility; for instance, QIAGEN reported in its 'Q3 2025 Results' in November 2025 that revenue for the twelve months ending September 30, 2025, reached $2.07 billion, underscoring persistent demand for molecular testing solutions.

Market Challenge

The expansion of the Global qPCR Instruments Market is heavily hindered by stringent regulatory frameworks governing in vitro diagnostics. This complicated compliance landscape places significant operational demands on manufacturers, necessitating extensive technical documentation and rigorous clinical evidence to achieve device certification. As companies are compelled to reallocate capital and staff to meet these elevated standards, resources meant for the research and development of next-generation qPCR platforms are inevitably diminished. As a result, the launch of advanced diagnostic tools is postponed, and manufacturers are increasingly reluctant to enter markets characterized by high compliance costs or uncertain approval timelines.

The tangible effect of these regulatory obstacles is reflected in the strategic choices major industry players make regarding market entry. According to MedTech Europe, in 2024, large in vitro diagnostic manufacturers indicated a 40% decrease in selecting the European Union as their primary region for initial product launches compared to earlier regulatory systems. This pattern illustrates how compliance difficulties actively deter the commercialization of new technologies. By retarding the speed of product innovation and establishing barriers to market access, these regulations directly limit the availability of novel solutions and suppress the overall growth of the qPCR instruments sector.

Market Trends

Manufacturers are actively pursuing the development of compact, battery-powered, and portable qPCR devices to facilitate decentralized testing in emergency departments, clinics, and field settings. This trend toward miniaturization permits healthcare professionals to perform advanced molecular diagnostics at the point of care, thereby drastically shortening turnaround times relative to conventional centralized laboratories. The swift uptake of these streamlined systems is demonstrated by the rising demand for platforms engineered specifically for non-laboratory contexts. According to bioMerieux's 'First-Half 2025 Financial Results' in September 2025, organic sales for the SPOTFIRE point-of-care system rose by 143% over the prior year, emphasizing the sector's strong shift toward accessible, near-patient testing options.

At the same time, there is a marked increase in high-multiplicity multiplexing capabilities, spurred by the essential need to identify multiple targets, such as complex pathogen panels, within a single reaction. Laboratories are favoring instruments capable of analyzing numerous channels simultaneously to conserve precious patient samples and enhance diagnostic efficiency, advancing beyond basic single-target assays. This requirement for comprehensive syndromic testing is transforming product portfolios as companies incorporate broader detection menus and higher channel counts. According to QIAGEN's 'Q3 2025 Results' in November 2025, sales of the QIAstat-Dx syndromic testing platform increased by 11% at constant exchange rates, indicating a robust market preference for advanced multiplexing technologies that optimize workflow productivity.

Key Market Players

  • Thermo Fisher Scientific, Inc.
  • F. Hoffmann-La Roche Ltd.
  • AstraZeneca Inc.
  • Bio-Rad Laboratories, Inc.
  • Danaher Corporation
  • QIAGEN N.V.
  • Agilent Technologies, Inc.
  • Abbott Laboratories Inc.
  • Azure Biosystems Inc.
  • Bio Molecular Systems Pty Ltd

Report Scope

In this report, the Global qPCR Instruments Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

qPCR Instruments Market, By Test Type

  • 7500
  • QuantStudio Dx
  • QuantStudio 5
  • ViiA 7 Dx
  • One Step/One
  • Step Plus
  • LightCycler 2.0
  • Cobas 4800
  • CFX96
  • SmartCycler
  • GeneXpert
  • Rotor-Gene Q 5Plex HRM System
  • Rotor-Gene Q
  • BIOFIRE FILMARRAY SYSTEMS
  • BMS Mic System

qPCR Instruments Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global qPCR Instruments Market.

Available Customizations:

Global qPCR Instruments Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global qPCR Instruments Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (7500, QuantStudio Dx, QuantStudio 5, ViiA 7 Dx, One Step/One, Step Plus, LightCycler 2.0, Cobas 4800, CFX96, SmartCycler, GeneXpert, Rotor-Gene Q 5Plex HRM System, Rotor-Gene Q, BIOFIRE FILMARRAY SYSTEMS, BMS Mic System)
    • 5.2.2. By Region
    • 5.2.3. By Company (2025)
  • 5.3. Market Map

6. North America qPCR Instruments Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States qPCR Instruments Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
    • 6.3.2. Canada qPCR Instruments Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
    • 6.3.3. Mexico qPCR Instruments Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type

7. Europe qPCR Instruments Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany qPCR Instruments Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
    • 7.3.2. France qPCR Instruments Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
    • 7.3.3. United Kingdom qPCR Instruments Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
    • 7.3.4. Italy qPCR Instruments Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
    • 7.3.5. Spain qPCR Instruments Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type

8. Asia Pacific qPCR Instruments Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China qPCR Instruments Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
    • 8.3.2. India qPCR Instruments Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
    • 8.3.3. Japan qPCR Instruments Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
    • 8.3.4. South Korea qPCR Instruments Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
    • 8.3.5. Australia qPCR Instruments Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type

9. Middle East & Africa qPCR Instruments Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia qPCR Instruments Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
    • 9.3.2. UAE qPCR Instruments Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
    • 9.3.3. South Africa qPCR Instruments Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type

10. South America qPCR Instruments Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil qPCR Instruments Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
    • 10.3.2. Colombia qPCR Instruments Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
    • 10.3.3. Argentina qPCR Instruments Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global qPCR Instruments Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Thermo Fisher Scientific, Inc.
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. F. Hoffmann-La Roche Ltd.
  • 15.3. AstraZeneca Inc.
  • 15.4. Bio-Rad Laboratories, Inc.
  • 15.5. Danaher Corporation
  • 15.6. QIAGEN N.V.
  • 15.7. Agilent Technologies, Inc.
  • 15.8. Abbott Laboratories Inc.
  • 15.9. Azure Biosystems Inc.
  • 15.10. Bio Molecular Systems Pty Ltd

16. Strategic Recommendations

17. About Us & Disclaimer